

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 9, 2025

LDL Receptor antibody [EP1553Y]

RRID:AB_881213

Type: Antibody

Proper Citation

(Abcam Cat# ab52818, RRID:AB_881213)

Antibody Information

URL: http://antibodyregistry.org/AB_881213

Proper Citation: (Abcam Cat# ab52818, RRID:AB_881213)

Target Antigen: LDL Receptor antibody [EP1553Y]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Flow Cyt, ICC/IF, IHC-P, IP, WB; Flow Cytometry; Western Blot; Immunohistochemistry - fixed; Immunocytochemistry; Immunofluorescence; Immunohistochemistry; Immunoprecipitation

Antibody Name: LDL Receptor antibody [EP1553Y]

Description: This monoclonal targets LDL Receptor antibody [EP1553Y]

Target Organism: rat, mouse, human

Antibody ID: AB_881213

Vendor: Abcam

Catalog Number: ab52818

Record Creation Time: 20241016T233925+0000

Record Last Update: 20241017T010300+0000

Ratings and Alerts

No rating or validation information has been found for LDL Receptor antibody [EP1553Y].

No alerts have been found for LDL Receptor antibody [EP1553Y].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Fabiano M, et al. (2024) Presenilin Deficiency Results in Cellular Cholesterol Accumulation by Impairment of Protein Glycosylation and NPC1 Function. International journal of molecular sciences, 25(10).

Wang W, et al. (2024) Engineering lentivirus envelope VSV-G for liver targeted delivery of IDOL-shRNA to ameliorate hypercholesterolemia and atherosclerosis. Molecular therapy. Nucleic acids, 35(1), 102115.

Brace EJ, et al. (2022) Distinct developmental and degenerative functions of SARM1 require NAD⁺ hydrolase activity. PLoS genetics, 18(6), e1010246.

Kakava S, et al. (2022) Brain Endothelial Cells in Contrary to the Aortic Do Not Transport but Degrade Low-Density Lipoproteins via Both LDLR and ALK1. Cells, 11(19).

Stomberski CT, et al. (2022) A multienzyme S-nitrosylation cascade regulates cholesterol homeostasis. Cell reports, 41(4), 111538.

Xu M, et al. (2021) Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine, 65, 103250.

Shi Y, et al. (2021) Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron, 109(15), 2413.

Wang X, et al. (2021) Receptor-Mediated ER Export of Lipoproteins Controls Lipid Homeostasis in Mice and Humans. Cell metabolism, 33(2), 350.

Chen Z, et al. (2021) LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway. Molecular metabolism, 51, 101230.

Weber M, et al. (2020) Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in

mice and highlights potential lipid biomarkers for human NAFLD. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 34(9), 11816.

Zhang C, et al. (2020) BLOS1 mediates kinesin switch during endosomal recycling of LDL receptor. eLife, 9.

Carreras A, et al. (2019) In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. BMC biology, 17(1), 4.

Becares N, et al. (2019) Impaired LXR? Phosphorylation Attenuates Progression of Fatty Liver Disease. Cell reports, 26(4), 984.